{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:28:51Z","timestamp":1790296131663,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DFG Research Infrastructure NGS_CC","award":["407495230"],"award-info":[{"award-number":["407495230"]}]},{"name":"Next Generation Sequencing Competence Network","award":["423957469"],"award-info":[{"award-number":["423957469"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interleukin (IL)-13 is a key driver of inflammation and barrier dysfunction in atopic dermatitis (AD). While there is robust evidence that tralokinumab \u2013 a monoclonal antibody that neutralizes IL-13 \u2013 reduces inflammation and clinical disease activity, less is known about its effects on barrier function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterize the effects of tralokinumab treatment on skin barrier function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transepidermal water loss (TEWL), stratum corneum hydration (SCH), natural moisturizing factor content, histopathological characteristics, biomarker expression and microbiome composition were evaluated in lesional, nonlesional and sodium lauryl sulfate-irritated skin of 16 patients with AD over the course of 16 weeks of tralokinumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All clinical severity scores decreased significantly over time. At week 16, mean TEWL in target lesions decreased by 33% (P = 0.01) and SCH increased by 58% (P = 0.004), along with a histological reduction in spongiosis (P = 0.003), keratin 16 expression and epidermal thickness (P = 0.001). In parallel, there was a significant decrease in several barrier dysfunction-associated and proinflammatory proteins such as fibronectin (P = 0.006), CCL17\/TARC (P = 0.03) and IL-8 (P = 0.01), with significant changes seen as early as week 8. Total bacterial load and Staphylococcus aureus abundance were significantly reduced from week 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tralokinumab treatment improved skin physiology, epidermal pathology and dysbiosis, further highlighting the pleiotropic role of IL-13 in AD pathogenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae138","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T22:39:07Z","timestamp":1711492747000},"page":"344-350","source":"Crossref","is-referenced-by-count":32,"title":["Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis"],"prefix":"10.1093","volume":"191","author":[{"given":"Nicole","family":"Sander","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"St\u00f6lzl","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Fonfara","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1842-8219","authenticated-orcid":false,"given":"Jan","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inken","family":"Harder","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3270-4884","authenticated-orcid":false,"given":"Ina","family":"Suhrkamp","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivone","family":"Jaka\u0161a","sequence":"additional","affiliation":[{"name":"Laboratory for Analytical Chemistry, Department of Chemistry and Biochemistry, Faculty of Food Technology and Biotechnology, University of Zagreb , Zagreb , Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"van den Bogaard","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud Institute for Medical Innovation , Radboudumc, Nijmegen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne","family":"van Vlijmen-Willems","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Radboud Institute for Medical Innovation , Radboudumc, Nijmegen , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Szymczak","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry and Statistics, University of L\u00fcbeck , L\u00fcbeck , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-3950","authenticated-orcid":false,"given":"Elke","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Gerdes","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein , Campus Kiel, Kiel , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"2024081418365348600_ljae138-B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"2024081418365348600_ljae138-B2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.16934","article-title":"Atopic dermatitis: the skin barrier and beyond","volume":"180","author":"Tsakok","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024081418365348600_ljae138-B3","doi-asserted-by":"crossref","first-page":"100131","DOI":"10.1016\/j.xjidi.2022.100131","article-title":"Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis","volume":"2","author":"Beck","year":"2022","journal-title":"JID Innov"},{"key":"2024081418365348600_ljae138-B4","doi-asserted-by":"crossref","first-page":"00888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"},{"key":"2024081418365348600_ljae138-B5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2024081418365348600_ljae138-B6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2020.06.012","article-title":"Atopic dermatitis displays stable and dynamic skin transcriptome signatures","volume":"147","author":"M\u00f6bus","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024081418365348600_ljae138-B7","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/jdv.13160","article-title":"Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin","volume":"29","author":"Szegedi","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024081418365348600_ljae138-B8","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw2938","article-title":"A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis","volume":"5","author":"Bitton","year":"2020","journal-title":"Sci Immunol"},{"key":"2024081418365348600_ljae138-B9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"2024081418365348600_ljae138-B10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2340\/00015555-3810","article-title":"Skin barrier and inflammation genes associated with atopic dermatitis are regulated by interleukin-13 and modulated by tralokinumab in vitro","volume":"101","author":"Tollenaere","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2024081418365348600_ljae138-B11","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.jaci.2020.02.026","article-title":"ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation","volume":"145","author":"Leyva-Castillo","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2024081418365348600_ljae138-B12","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaci.2023.02.013","article-title":"Stratum corneum lipid and cytokine biomarkers at age 2\u2005months predict the future onset of atopic dermatitis","volume":"151","author":"Berdyshev","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2024081418365348600_ljae138-B13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024081418365348600_ljae138-B14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024081418365348600_ljae138-B15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024081418365348600_ljae138-B16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jaad.2022.11.047","article-title":"Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial","volume":"88","author":"Beck","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024081418365348600_ljae138-B17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjd.17633","article-title":"Anatomical site differences of sodium lauryl sulfate-induced irritation: randomized controlled trial","volume":"181","author":"Leskur","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024081418365348600_ljae138-B18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-0536.1997.tb00041.x","article-title":"Guidelines on sodium lauryl sulfate (SLS) exposure tests","volume":"37","author":"Tupker","year":"1997","journal-title":"Contact Dermatitis"},{"key":"2024081418365348600_ljae138-B19","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/exd.14185","article-title":"Stratum corneum lipidomics analysis reveals altered ceramide profile in atopic dermatitis patients across body sites with correlated changes in skin microbiome","volume":"30","author":"Emmert","year":"2021","journal-title":"Exp Dermatol"},{"key":"2024081418365348600_ljae138-B20","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1111\/all.15742","article-title":"Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis","volume":"78","author":"Hartmann","year":"2023","journal-title":"Allergy"},{"key":"2024081418365348600_ljae138-B21","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis","volume":"151","author":"Bakker","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2024081418365348600_ljae138-B22","article-title":"Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies","volume":"101","author":"De Bruin-Weller","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2024081418365348600_ljae138-B23","author":"CRAN"},{"key":"2024081418365348600_ljae138-B24","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team"},{"key":"2024081418365348600_ljae138-B25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2024081418365348600_ljae138-B26","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jaci.2018.01.019","article-title":"Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration","volume":"141","author":"Baurecht","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024081418365348600_ljae138-B27","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","article-title":"Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses","volume":"145","author":"Tsoi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2024081418365348600_ljae138-B28","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2024081418365348600_ljae138-B29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","article-title":"Atopic dermatitis in African American patients is TH2\/TH22-skewed with TH1\/TH17 attenuation","volume":"122","author":"Sanyal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024081418365348600_ljae138-B30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/all.14490","article-title":"Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin","volume":"76","author":"Pavel","year":"2021","journal-title":"Allergy"},{"key":"2024081418365348600_ljae138-B31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024081418365348600_ljae138-B32","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"2024081418365348600_ljae138-B33","doi-asserted-by":"crossref","first-page":"100066","DOI":"10.1016\/j.xjidi.2021.100066","article-title":"Identification of keratinocyte mitogens: implications for hyperproliferation in psoriasis and atopic dermatitis","volume":"2","author":"Niehues","year":"2021","journal-title":"JID Innov"},{"key":"2024081418365348600_ljae138-B34","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.3389\/fmicb.2017.02433","article-title":"Staphylococcal adhesion and host cell invasion: fibronectin-binding and other mechanisms","volume":"8","author":"Josse","year":"2017","journal-title":"Front Microbiol"},{"key":"2024081418365348600_ljae138-B35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention","volume":"20","author":"Cambier","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"2024081418365348600_ljae138-B36","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/all.15153","article-title":"Assessment of biomarkers in pediatric atopic dermatitis by tape strips and skin biopsies","volume":"77","author":"Andersson","year":"2022","journal-title":"Allergy"},{"key":"2024081418365348600_ljae138-B37","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1101\/gr.131029.111","article-title":"Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis","volume":"22","author":"Kong","year":"2012","journal-title":"Genome Res"},{"key":"2024081418365348600_ljae138-B38","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaci.2023.05.026","article-title":"Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following\u00a0dupilumab treatment","volume":"152","author":"Simpson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2024081418365348600_ljae138-B39","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1111\/all.15432","article-title":"Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis","volume":"77","author":"Berdyshev","year":"2022","journal-title":"Allergy"},{"key":"2024081418365348600_ljae138-B40","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jdv.19081","article-title":"The impact of dupilumab on skin barrier function: a systematic review","volume":"37","author":"Montero-Vilchez","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae138\/57448588\/ljae138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/3\/344\/58820402\/ljae138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/3\/344\/58820402\/ljae138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T14:38:01Z","timestamp":1723646281000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/3\/344\/7635475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,26]]},"published-print":{"date-parts":[[2024,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae138","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,3,26]]}}}